CXCL13 and systemic lupus erythematosus: Since we saw less than a full reversal of the NPSLE phenotype with CXCL13 inhibition, for future studies it may be beneficial to explore different dosages and/or frequency of delivery and to also test the same treatment in other lupus-prone mouse models with neuropsychiatric presentations to see if the treatment is equally advantageous.